MUREPAVADIN

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C73H112N22O16
Molecular Weight	1553.8082
Optical Activity	UNSPECIFIED
Defined Stereocenters	16 / 16
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

[H][C@@]12CCCN1C(=O)[C@@]3([H])CCCN3C(=O)[C@H](CO)NC(=O)[C@H](C)NC(=O)[C@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@H](CC4=CNC5=CC=CC=C45)NC(=O)[C@H](CCN)NC(=O)[C@@H](CCN)NC(=O)[C@H](CCCN)NC(=O)[C@H](CCN)NC(=O)[C@@]([H])(NC(=O)[C@H](CC6=CNC7=CC=CC=C67)NC(=O)[C@@]([H])(NC2=O)[C@@H](C)O)[C@@H](C)CC

InChI

InChIKey=RIDRXGOBXZLKHZ-NZUANIILSA-N

InChI=1S/C73H112N22O16/c1-5-38(2)58-70(108)88-52(24-30-79)65(103)83-47(17-10-25-74)62(100)85-49(21-27-76)63(101)86-51(23-29-78)66(104)89-53(33-41-35-80-45-15-8-6-13-43(41)45)67(105)87-50(22-28-77)64(102)84-48(20-26-75)61(99)82-39(3)60(98)91-55(37-96)72(110)95-32-12-19-57(95)73(111)94-31-11-18-56(94)69(107)93-59(40(4)97)71(109)90-54(68(106)92-58)34-42-36-81-46-16-9-7-14-44(42)46/h6-9,13-16,35-36,38-40,47-59,80-81,96-97H,5,10-12,17-34,37,74-79H2,1-4H3,(H,82,99)(H,83,103)(H,84,102)(H,85,100)(H,86,101)(H,87,105)(H,88,108)(H,89,104)(H,90,109)(H,91,98)(H,92,106)(H,93,107)/t38-,39-,40+,47-,48-,49+,50-,51-,52-,53-,54-,55-,56-,57+,58-,59-/m0/s1

HIDE SMILES / InChI

Molecular Formula	C73H112N22O16
Molecular Weight	1553.8082
Charge	0
Count

Stereochemistry	ABSOLUTE
Additional Stereochemistry	No
Defined Stereocenters	16 / 16
E/Z Centers	0
Optical Activity	UNSPECIFIED

Description
Sources: https://www.ncbi.nlm.nih.gov/pubmed/29901750 | https://www.ncbi.nlm.nih.gov/pubmed/30642931 | https://www.ncbi.nlm.nih.gov/pubmed/30012756 | https://clinicaltrials.gov/ct2/show/NCT03409679 | https://www.polyphor.com/pol7080/

Murepavadin is the first in class of the outer membrane protein-targeting antibiotics (OMPTA) and a pathogen-specific peptidomimetic antibacterial with a novel, nonlytic mechanism of action targeting Pseudomonas aeruginosa. Murepavadin is being developed by Polyphor Ltd for the treatment of hospital-acquired bacterial pneumonia (HABP) and ventilator-associated bacterial pneumonia. In preclinical studies, Murepavadin was highly effective against Pseudomonas aeruginosa, without evidence of generating resistance. Murepavadin has been evaluated in 8 clinical studies. Murepavadin penetrates into lung tissue and showed encouraging results in a Phase II study when given on top of standard of care in patients with Ventilator-Associated Bacterial Pneumonia. The phase III clinical trial was initiated in 2018 to assess the efficacy, safety, and tolerability of Murepavadin in adult subjects with ventilator-associated bacterial pneumonia. But in May 2019, Polyphor Ltd. suspended the global phase III trial for safety data review.

Originator

Approval Year

PubMed

Title	Date	PubMed

Patents

Sample Use Guides

In Vivo Use Guide

single dose: Murepavadin 4.5 mg/kg as 3-h IV infusion multiply doses: Murepavadin IV every 8 hours + 1 anti-pseudomonal antibiotic

Route of Administration: Intravenous

Substance Class	Chemical Created by `admin` on `Sat Dec 16 05:03:18 UTC 2023` Edited by `admin` on `Sat Dec 16 05:03:18 UTC 2023`
Record UNII	0D02GRY87Z
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

MUREPAVADIN

Official Name

English

POL7080

Code

English

murepavadin [INN]

Common Name

English

RO-7033877

Code

English

Murepavadin [WHO-DD]

Common Name

English

RO7033877

Code

English

CYCLO(L-ALANYL-L-SERYL-D-PROLYL-L-PROLYL-L-THREONYL-L-TRYPTOPHYL-L-ISOLEUCYL-(2S)-2,4-DIAMINOBUTANOYL-L-ORNITHYL-(2R)-2,4-DIAMINOBUTANOYL-(2S)-2,4-DIAMINOBUTANOYL-L-TRYPTOPHYL-(2S)-2,4-DIAMINOBUTANOYL-(2S)-2,4-DIAMINOBUTANOYL)

Common Name

English

POL-7080

Code

English

MUREPAVADIN [USAN]

Common Name

English

Code System Code Type Description

SMS_ID

100000175060